TOKYO, JAPAN – May 14, 2025 –

日本东京——2025年5月14日——

Terumo Corporation (TSE: 4543) today announced that it has reached an agreement with WuXi Biologics for Terumo to acquire WuXi Biologics’ drug product (DP) plant located in Leverkusen, Germany for 150 million Euro (about 24.6 billion yen*1).

泰尔茂公司（TSE: 4543）今天宣布，已与药明生物达成协议，以1.5亿欧元（约合246亿日元*1）收购药明生物位于德国勒沃库森的药品生产（DP）工厂。

Terumo develops containers such as prefilled syringes and drug delivery devices using materials suitable for pharmaceuticals. The company also engages in the CDMO*2 business for combination products of pharmaceuticals and medical devices, leveraging advanced manufacturing technologies. Terumo positions the globalization of the CDMO business as one of its future growth strategies..

泰尔茂开发使用适合医药材料的容器，例如预充式注射器和药物输送装置。公司还利用先进的制造技术，从事药品和医疗器械组合产品的CDMO*2业务。泰尔茂将CDMO业务的全球化定位为其未来增长战略之一。

Terumo aims to expand production capacity and strengthen its global responsiveness by utilizing the newly acquired DP plant as its first overseas CDMO production base. This will accelerate the global expansion of the CDMO business.

泰尔茂旨在通过利用新收购的DP工厂作为其首个海外CDMO生产基地，扩大生产能力并增强其全球响应能力。这将加速CDMO业务的全球扩展。

The DP plant acquired from WuXi Biologics is equipped with state-of-the-art facilities compliant with GMP*3 standards. It is also staffed with highly skilled personnel, production know-how, and a proven track record. Leveraging these assets, Terumo will commence the development and production of prefilled syringe products and vial products at the plant.

从药明生物收购的DP工厂配备了符合GMP*3标准的最先进的设施，还拥有高技能的人员、生产技术诀窍和经验证的成功记录。利用这些资源，泰尔茂将在这座工厂开始开发和生产预灌封注射器产品及西林瓶产品。

This will enable the company to address the growing demand for CDMO services, particularly in Europe and the United States, driven by the rapid growth of biopharmaceuticals..

这将使公司能够应对对CDMO服务不断增长的需求，特别是在欧洲和美国，这种需求是由生物制药的快速增长所推动的。

Currently, Terumo has CDMO production bases at the Kofu, Fujinomiya, and Yamaguchi factories. The company has continuously enhanced its production capacity in line with the expansion of the CDMO business. In December 2023, Terumo expanded the CDMO production capabilities by expanding the production lines at the Yamaguchi factory.

目前，泰尔茂在甲府、富士宫和山口工厂拥有CDMO生产基地。公司随着CDMO业务的扩展，持续提升生产能力。2023年12月，泰尔茂通过扩建山口工厂的生产线，进一步扩大了CDMO的生产能力。

Additionally, the company is in the process of installing new production lines in the Kofu factory’s newly constructed building, which is currently under construction and scheduled for completion in fiscal 2025. By establishing a new CDMO production base in Europe, Terumo aims to strengthen its global operations to meet the growing needs of pharmaceutical companies both domestically and internationally..

此外，该公司正在甲府工厂的新建建筑中安装新的生产线，该建筑目前正在建设中，预计将于2025财年完工。通过在欧洲建立一个新的CDMO生产基地，泰尔茂旨在加强其全球运营，以满足国内外制药公司不断增长的需求。

'The acquisition of the drug product plant is a pivotal step in enhancing the competitiveness of our CDMO business, and we are thrilled to have reached an agreement with WuXi Biologics,” said Hikaru Samejima, Chief Executive Officer, Terumo Corporation. “By integrating the high-quality and stable production operations of the Leverkusen plant and the exceptional talent supporting it with Terumo, we are confident that we will significantly elevate the global responsiveness of our CDMO business.'.

“收购该药品生产厂是我们提升CDMO业务竞争力的关键一步，我们很高兴与药明生物达成协议，”泰尔茂公司首席执行官龟岛彦表示。“通过将勒沃库森工厂高质量、稳定的生产运营及其背后卓越的人才与泰尔茂相结合，我们相信将大幅提升我们CDMO业务的全球响应能力。”

Overview of the drug product plant to be acquired from WuXi Biologics

概述将从药明生物收购的药物产品工厂

Location                              Leverkusen, North Rhine-Westphalia, Germany

地点                                勒沃库森，北莱茵-威斯特法伦州，德国

Site area of the plant        13,000㎡

工厂占地面积 13,000平方米

Description of business   CDMO business for vial products (as of May 2025)

业务描述 西林瓶产品的CDMO业务（截至2025年5月）

Number of employees      Approximately 150

员工人数：约150人

*1 Converted at an exchange rate of 1 Euro to 164 yen

*1 按1欧元兑换164日元的汇率转换

*2 Contract Development and Manufacturing Organization

*2 合同开发和制造组织

*3 Good Manufacturing Practice

*3 良好生产规范

(Reference) Terumo’s CDMO business

（参考）泰尔茂的CDMO业务

Through partnerships, Terumo's CDMO business supports pharmaceutical companies in the design, manufacturing and regulatory approval processes of combination products. Since biopharmaceuticals are mainly administered as injectables, the importance of developing appropriate containers and delivery devices tailored to the characteristics of the drugs, as well as technologies for aseptic filling of drugs, is increasing.

通过合作，Terumo的CDMO业务支持制药公司在组合产品的设计、制造和监管审批流程。由于生物制药主要以注射剂形式给药，因此开发适合药物特性适用的容器和递送装置，以及无菌灌装技术的重要性日益增加。

Leveraging its unique technologies and expertise cultivated through prefilled syringe products, Terumo develops and provides delivery devices such as injection needles and syringe pumps. These devices globally support pharmaceutical companies in resolving drug-related challenges and enhancing the value of pharmaceuticals..

利用通过预充式注射器产品培育的独特技术和专业知识，泰尔茂开发并提供诸如注射针头和注射泵等输送装置。这些设备在全球范围内支持制药公司解决药物相关挑战并提升药品价值。